{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:48:10Z","timestamp":1790045290062,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jval.2022.06.010","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T01:38:43Z","timestamp":1660181923000},"page":"1696-1704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands"],"prefix":"10.1016","volume":"25","author":[{"given":"Rimma","family":"Velikanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"van der Schans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf Walther","family":"van Olden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jval.2022.06.010_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"issue":"8","key":"10.1016\/j.jval.2022.06.010_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.jval.2022.06.010_bib3","first-page":"1400","article-title":"A\u00a0natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"4","key":"10.1016\/j.jval.2022.06.010_bib4","first-page":"503","article-title":"One year of newborn screening for SMA \u2013 results of a German pilot project","volume":"6","author":"Vill","year":"2019","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.jval.2022.06.010_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am J Med Genet"},{"issue":"1","key":"10.1016\/j.jval.2022.06.010_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy \u2013 a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jval.2022.06.010_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"18","key":"10.1016\/j.jval.2022.06.010_bib9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2022.06.010_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"10.1016\/j.jval.2022.06.010_bib11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2022.06.010_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.jval.2022.06.010_bib13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.jval.2022.06.010_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.jval.2022.06.010_bib15","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/brain\/awf155","article-title":"Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord","volume":"125","author":"Soler-Botija","year":"2002","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jval.2022.06.010_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2019.11.002","article-title":"244th ENMC international workshop: newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands","volume":"30","author":"Dangouloff","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.jval.2022.06.010_bib17","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41431-019-0415-4","article-title":"Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors","volume":"27","author":"Serra-Juhe","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jval.2022.06.010_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening","volume":"190","author":"Chien","year":"2017","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.jval.2022.06.010_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","article-title":"The implementation of newborn screening for spinal muscular atrophy: the Australian experience","volume":"22","author":"Kariyawasam","year":"2020","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.jval.2022.06.010_bib20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in New York state","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.jval.2022.06.010_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":"Newborn screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.jval.2022.06.010_bib22","first-page":"145","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J\u00a0Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.jval.2022.06.010_bib23","first-page":"109","article-title":"Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening \u2013 opportunity or burden? [published correction appears in J Neuromuscul Dis. 2021;8(2):335-336]","volume":"7","author":"M\u00fcller-Felber","year":"2020","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.jval.2022.06.010_bib25","author":"Heijnen"},{"issue":"1","key":"10.1016\/j.jval.2022.06.010_bib26","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.jval.2022.06.010_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","article-title":"Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US","volume":"18","author":"Thokala","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"10.1016\/j.jval.2022.06.010_bib29","article-title":"An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)","volume":"9","author":"Dean","year":"2021","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.jval.2022.06.010_bib32","series-title":"Sun may arise on SMA: newborn screening of SMA","author":"Servais","year":"2020"},{"key":"10.1016\/j.jval.2022.06.010_bib36","series-title":"Kostenhandleiding: Methodologie van Kostenonderzoek en Referentieprijzen voor Economische Evaluaties in de Gezondheidszorg. Diemen","author":"Hakkaart-van Roijen","year":"2016"},{"key":"10.1016\/j.jval.2022.06.010_bib37","series-title":"Nusinersen for Treating Spinal Muscular Atrophy: A Single Technology Appraisal Erratum","author":"Tappenden","year":"2018"},{"issue":"9","key":"10.1016\/j.jval.2022.06.010_bib38","doi-asserted-by":"crossref","first-page":"A725","DOI":"10.1016\/j.jval.2017.08.1962","article-title":"The utility of different approaches to developing health utilities data in childhood rare diseases \u2013 a case study in spinal muscular atrophy (SMA)","volume":"20","author":"Thompson","year":"2017","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2022.06.010_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.pediatrneurol.2015.06.002","article-title":"Delay in diagnosis of spinal muscular atrophy: a systematic literature review","volume":"53","author":"Lin","year":"2015","journal-title":"Pediatr Neurol"},{"issue":"15suppl","key":"10.1016\/j.jval.2022.06.010_bib41","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1212\/WNL.94.15_supplement.1429","article-title":"Evaluation of nusinersen on impact of caregiver experience and HRQOL in later-onset spinal muscular atrophy (SMA): results from the phase 3 CHERISH trial","volume":"94","author":"Johnson","year":"2020","journal-title":"Neurology"},{"issue":"15 suppl","key":"10.1016\/j.jval.2022.06.010_bib43","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1212\/WNL.94.15_supplement.1640","article-title":"Nusinersen in infantile-onset spinal muscular atrophy: results from a longer-term treatment from the Open-label SHINE Extension Study (1640)","volume":"94","author":"Castro","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jval.2022.06.010_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl Clin Genet"},{"issue":"21","key":"10.1016\/j.jval.2022.06.010_bib47","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jval.2022.06.010_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.earlhumdev.2019.104851","article-title":"Treating neonatal spinal muscular atrophy: a 21st century success story?","volume":"138","author":"Tizzano","year":"2019","journal-title":"Early Hum Dev"},{"issue":"18","key":"10.1016\/j.jval.2022.06.010_bib49","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2022.06.010_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.1016\/j.jval.2022.06.010_bib51","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the Phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"15suppl","key":"10.1016\/j.jval.2022.06.010_bib52","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1212\/WNL.96.15_supplement.2301","article-title":"Long-term follow-up (LTFU) of onasemnogene abeparvovec therapy in spinal muscular atrophy","volume":"96","author":"Mendell","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jval.2022.06.010_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.jval.2022.06.010_bib54","doi-asserted-by":"crossref","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","article-title":"Survival of patients with spinal muscular atrophy type 1","volume":"131","author":"Gregoretti","year":"2013","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jval.2022.06.010_bib55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.jval.2022.06.010_bib56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","article-title":"A\u00a0collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients","volume":"146","author":"Zerres","year":"1997","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.jval.2022.06.010_bib59","series-title":"Healthcare resource use and treatment patterns in spinal muscular atrophy: interviews with Healthcare Professionals in the UK [report]","year":"2019"},{"issue":"11","key":"10.1016\/j.jval.2022.06.010_bib60","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40273-016-0431-y","article-title":"From good to better: new Dutch guidelines for economic evaluations in healthcare","volume":"34","author":"Versteegh","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2022.06.010_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","article-title":"Standardizing the inclusion of indirect medical costs in economic evaluations","volume":"29","author":"Van Baal","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2022.06.010_bib62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2022.06.010_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2022.06.010_bib64","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","article-title":"Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis","volume":"92","author":"Shih","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.06.010_bib65","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jval.2020.04.805","article-title":"PMU30 cost-effectiveness analysis of newborn screening for spinal muscular atrophy (SMA) in the United States","volume":"23","author":"Arjunji","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.06.010_bib66","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","article-title":"Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy","volume":"227","author":"Jalali","year":"2020","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jval.2022.06.010_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-6606-7-17","article-title":"Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons","volume":"7","author":"Choi","year":"2014","journal-title":"Mol Brain"},{"issue":"17-18","key":"10.1016\/j.jval.2022.06.010_bib68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1089\/hum.2020.138","article-title":"Adeno-associated virus-based gene therapy for lifelong correction of genetic disease","volume":"31","author":"Brommel","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jval.2022.06.010_bib69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2017","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522020654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522020654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:27:01Z","timestamp":1761096421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522020654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1098301522020654"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.06.010","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}